Cover Image
市場調查報告書

B型流感病毒感染:開發中產品分析

Influenzavirus B Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484630
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
B型流感病毒感染:開發中產品分析 Influenzavirus B Infections - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 120 Pages
簡介

B型流感是零星發生並具有發射性傳染趨勢的流感病毒亞型。症候有鼻涕,咽喉炎,肌肉痛,不舒服,淚眼,身體疼痛,食慾衰退,衰弱等。治療有使用處方抗病毒藥物,止痛藥,退燒藥等。

本報告提供全球各國治療B型流感病毒感染所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介+

  • 調查範圍

B型流感病毒感染;概要

B型流感病毒感染 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Altravax Inc
  • Amarillo Biosciences Inc
  • Aphios Corp
  • BioClonetics Immunotherapeutics Inc
  • ContraFect Corp
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Ilyang Pharmaceutical Co Ltd
  • Kineta Inc
  • Medicago Inc
  • MedImmune LLC
  • Mucosis BV
  • Novavax Inc
  • Protein Sciences Corp
  • Romark Laboratories LC
  • Sanofi Pasteur SA
  • 鹽野義製藥
  • SK Chemicals Co Ltd
  • 富山化學工業
  • TSRL Inc
  • Vaxart Inc
  • Vectura Group Plc
  • Zydus Cadila Healthcare Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9687IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2017, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 15, 2, 3, 9 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 2, 1 and 2 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Influenzavirus B Infections - Overview
  • Influenzavirus B Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Influenzavirus B Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Influenzavirus B Infections - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Adimmune Corp
  • Altravax Inc
  • Amarillo Biosciences Inc
  • Aphios Corp
  • BioCryst Pharmaceuticals Inc
  • Cadila Healthcare Ltd
  • ContraFect Corp
  • Daiichi Sankyo Company Ltd
  • Fujifilm Holdings Corporation
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Inovio Pharmaceuticals Inc
  • Kineta Inc
  • Medicago Inc
  • MedImmune LLC
  • Mucosis BV
  • Novavax Inc
  • Park Active Molecules
  • Romark Laboratories LC
  • Sanofi
  • Sanofi Pasteur SA
  • Shionogi & Co Ltd
  • SK Chemicals Co Ltd
  • TSRL Inc
  • Vaxart Inc
  • Vectura Group Plc
  • Influenzavirus B Infections - Drug Profiles
  • AL-18 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APP-0205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APP-309 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CF-403 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CF-404 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • favipiravir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fluad (quadrivalent) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GC-3106A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Influenzavirus B Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B/victoria+ B/yamagata] (quadrivalent, split virion) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (split virion) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • interferon alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KIN-1400 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • laninamivir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody for Influenza B Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NBP-607 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nitazoxanide CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PAM-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • peramivir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S-033188 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VR-736 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VXABYW-10 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • zanamivir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • zanamivir - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Influenzavirus B Infections - Dormant Projects
  • Influenzavirus B Infections - Discontinued Products
  • Influenzavirus B Infections - Product Development Milestones
  • Featured News & Press Releases
  • Jul 24, 2017: Shionogi Announces Positive Top-Line Results for S-033188 Phase 3 Study (CAPSTONE-1) in Otherwise Healthy Influenza Patients
  • Jun 20, 2017: Sanofi Pasteur receives MFDS Approval for VaxigripTetra inj., a New Four-Strain Influenza Vaccine
  • Mar 06, 2017: TSRL Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza
  • Dec 01, 2016: Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released
  • Aug 29, 2016: Seqirus receives FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
  • Aug 29, 2016: Shionogi Presents Results from a Phase 2 Proof-of-Concept Clinical Trial and Non-Clinical Studies of S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza
  • Aug 26, 2016: Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg
  • Aug 25, 2016: VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccine Fluad in Austria
  • Jun 23, 2016: New Four-Strain Influenza Vaccine, VaxigripTetra, regulatory dossier from Sanofi Pasteur now approved in Europe
  • Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
  • Feb 12, 2016: Protein Sciences and UNIGEN Reach Agreement to Source Flublok Influenza Vaccine from Japan
  • Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial
  • Jun 04, 2015: Kineta's Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections
  • May 12, 2015: Kineta Presents Data On Novel Antiviral Compounds Which Inhibit Broad Spectrum of Respiratory Diseases At International Antiviral Conference
  • Nov 03, 2014: Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone High-Dose Vaccine for Adults 65 and Older
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Influenzavirus B Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Influenzavirus B Infections - Pipeline by AbbVie Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Adimmune Corp, H2 2017
  • Influenzavirus B Infections - Pipeline by Altravax Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Amarillo Biosciences Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Aphios Corp, H2 2017
  • Influenzavirus B Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Influenzavirus B Infections - Pipeline by ContraFect Corp, H2 2017
  • Influenzavirus B Infections - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Influenzavirus B Infections - Pipeline by Fujifilm Holdings Corporation, H2 2017
  • Influenzavirus B Infections - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Influenzavirus B Infections - Pipeline by Green Cross Corp, H2 2017
  • Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Kineta Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Medicago Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by MedImmune LLC, H2 2017
  • Influenzavirus B Infections - Pipeline by Mucosis BV, H2 2017
  • Influenzavirus B Infections - Pipeline by Novavax Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Park Active Molecules, H2 2017
  • Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H2 2017
  • Influenzavirus B Infections - Pipeline by Sanofi, H2 2017
  • Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H2 2017
  • Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H2 2017
  • Influenzavirus B Infections - Pipeline by SK Chemicals Co Ltd, H2 2017
  • Influenzavirus B Infections - Pipeline by TSRL Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Vaxart Inc, H2 2017
  • Influenzavirus B Infections - Pipeline by Vectura Group Plc, H2 2017
  • Influenzavirus B Infections - Dormant Projects, H2 2017
  • Influenzavirus B Infections - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Influenzavirus B Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top